Pfizer Reports Modest Growth Amid Market Challenges in Q2 FY24-25

Pfizer has recently undergone an adjustment in evaluation, reflecting the company's current market dynamics and financial metrics. The pharmaceuticals and drugs giant has been navigating a challenging landscape, with its recent financial disclosures indicating a modest growth trajectory. For the second quarter of FY24-25, net sales exhibited a growth rate of 0.70% year-over-year, while operating profit showed a slightly higher increase of 3.32% over the past five years.
In September 2024, Pfizer's operating cash flow reached Rs 256.84 crore, alongside a dividend per share of Rs 35.00. The company's debtors turnover ratio was reported at 9.84 times, which may suggest some liquidity considerations. The stock's technical indicators, including MACD and Bollinger Bands, are currently reflecting a trend that warrants attention.

Despite a return of 14.20% over the past year and a profit increase of 13.7%, Pfizer's valuation metrics indicate a relatively high price-to-book ratio of 5.8 and a PEG ratio of 2.6. The company continues to maintain a low debt-to-equity ratio, and there has been a slight uptick in institutional investor participation, now at 19.57%.

For more insights on Pfizer's financial trends and performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.